Regulatory Issues
4 articles on Regulatory Issues, written by Shotlee and medically reviewed for clinical accuracy.
What the War on Peptides Tells Us About Beauty's Future
Peptides are sweeping social media as injectables for clear skin, muscle gains, and fat loss, but a regulatory crackdown signals a war on unapproved versions. With FDA seizures, RFK Jr.'s advocacy, and black market persistence, what does this mean for beauty's future? Uncover the murky truths behind the hype.
5 min read
What Are Peptides? Are They Safe and Backed by Evidence?
Peptides are short amino acid chains hailed by influencers for weight loss, injury repair, and anti-aging, but is the hype backed by evidence? While approved drugs like Wegovy (semaglutide) show real benefits, unregulated peptides like BPC-157 lack human trials and raise safety flags from experts. Dive into the facts on peptides' potential and pitfalls.
6 min read
Entrepreneur Uses AI to Build $1B Telehealth Company on GLP-1 Drugs
Matthew Gallagher, a 41-year-old LA entrepreneur, turned $20,000 into a nearly $2 billion telehealth empire with AI alone. Medvi sells GLP-1 drugs like Ozempic at $300 versus $1,000 retail, serving 250,000 customers. But rapid growth sparks debates on legality and fake ads.
5 min read
Hims & Hers GLP-1 Pill Launch Backfires, Fuels Compounder Crackdown
Hims & Hers aimed to disrupt the GLP-1 market with a cheap oral semaglutide pill, but faced swift FDA backlash and a patent lawsuit from Novo Nordisk. The retreat highlights regulatory risks for compounders as branded supplies stabilize. This analysis reveals challenges in oral GLP-1 production and future paths for telehealth weight loss offerings.
6 min read